AIDS RELATED OPPORTUNISTIC PATHOGEN

虽然禽分枝杆菌复合体在临床上代表了一种 艾滋病患者中重要的机会性病原体缺乏 关于它们致病性的信息已经产生了一个关键的 科学上的空白，使治疗感染变得困难 这些微生物。这个问题最近在 NIH研讨会和巴斯德研究所论坛的形式旨在确定 并讨论在理解中重要的高优先级领域，如果 重要的机会主义病原体。这样做的长期目标是 研究提案是形成一个合作努力，这将导致 更好地理解已定义的三个重要领域 针对禽类分枝杆菌复合体、致病性、致病力和多重药物 抵抗。这将通过两个部门的共同努力来实现 在过去的一年里一直研究这些分枝杆菌的实验室 好几年了。具体目标将是阐明基本机制 定义了血清型特异性糖肽脂(GPL)的作用 致病性中的抗原并研究GPL的生物合成 这样就可以最终确定特定的代谢目标 改进抗分枝杆菌治疗。除了最初的六个月 访问，要求在接下来的两年内进行两次为期3个月的访问 句号。这两次访问的目的是完成将 在最初为期六个月的研究期间开始。这些单独的访问 将主要处理1)对新的禽类分枝杆菌脂类的分析 没有及时提纯到足够数量的第一次 访问和2)确定潜在的脂类前体 来自药物抑制研究。

Although the Mycobacterium avium complex represents a clinically significant group of opportunistic pathogens in AIDS patients, the lack of information regarding their pathogenicity has generated a critical scientific void that makes it difficult to treat infections involving these microorganisms. This problem has gained recent attention in the form of NIH Workshops and Institute Pasteur Forums designed to identify and discuss high-priority areas important in the understanding if these significant opportunistic pathogens. The long-term objective of this research proposal is to form a collaborative effort that will result in a better understanding of three important areas that have been defined for the M. avium complex, pathogenicity, virulence and multiple drug resistance. This will be accomplished by combining the efforts of two laboratories that have studied these mycobacteria throughout the last several years. Specific aims will be to elucidate the basic mechanisms that define the role of the serovar-specific glycopeptidolipid (GPL) antigens in pathogenicity and to investigate the biosynthesis of the GPL so that specific metabolic targets can eventually be identified to improve antimycobacterial therapy. In addition to the initial six-month visit, two 3-month visits are being requested for the following two year periods. The purpose of these two visits is to complete work that will be started during the initial six-month study. These separate visits will deal primarily with 1) the analysis of new M. avium lipids that will have not been purified in sufficient quantities in time for the first visit and 2) the identification of potential lipid precursors that result from drug inhibitory studies.